As of July 23, 2026, the US had confirmed 2,318 measles cases, surpassing the full-year 2025 total (2,289) and marking the highest count since 1991. Ninety-three percent of 2026 cases are ...

Serial amnioinfusions enabled lung development and live birth in most pregnancies complicated by fetal renal failure and anhydramnios. Survival beyond birth remains dependent on intensive neonatal ...

Jon Farber, MD, shares his thoughts on the diagnosis of slipped capital femoral epiphysis. The diagnosis of slipped capital femoral epiphysis (SCFE) in children whose presenting symptom is knee pain ...

Jon Farber, MD, shares his thoughts on the efficacy of laser therapy for temporal lobe epilepsy. A retrospective study in 19 children with mesial temporal lobe epilepsy who underwent laser ...

Individualized antisense oligonucleotide therapy was associated with reduced seizure burden and developmental gains in 2 children with SCN2A-related developmental epileptic encephalopathy.

Nearly 15% of King County children received MMRV as their first measles- or varicella-containing vaccine between 2015 and 2025, a share that did not change despite ACIP's longstanding preference for ...

VCA-894A received FDA rare pediatric disease designation for CMT2S, an ultrarare inherited neuropathy with limited treatment options. The FDA has granted rare pediatric disease designation to VCA-894A ...

Tegacorat received FDA orphan drug and rare pediatric disease designations for Duchenne muscular dystrophy. The FDA has granted orphan drug and rare pediatric disease designations to tegacorat (GRM-01 ...

About 25% of children with EoE have joint hypermobility, and this subgroup reports more autonomic symptoms, most commonly orthostatic light-headedness, and worse quality of life. Chronic headache in a ...

The FDA has accepted Pharvaris's NDA for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand HAE attack treatment, with a PDUFA date of April 23, 2027. In the Phase 3 RAPIDe-3 ...

A look back at the FDA approvals, regulatory decisions, and pipeline updates in the pediatric health care space from June 2026. Another month has come and gone, and with it, several FDA approvals and ...

The July 1, 2026 decision makes exagamglogene autotemcel the first gene therapy approved for SCD in children younger than 12 years. The FDA has issued a supplemental approval for Casgevy ...